Liver Disease Diagnostics Market by Diagnosis Technique (Biopsy, Endoscopy, Imaging), End-user (Hospitals, Laboratories) - Global Forecast 2024-2030

Liver Disease Diagnostics Market by Diagnosis Technique (Biopsy, Endoscopy, Imaging), End-user (Hospitals, Laboratories) - Global Forecast 2024-2030


The Liver Disease Diagnostics Market size was estimated at USD 9.94 billion in 2023 and expected to reach USD 11.09 billion in 2024, at a CAGR 12.76% to reach USD 23.05 billion by 2030.

The liver disease diagnostics market encompasses all technologies, products, and services dedicated to detecting and monitoring various liver conditions, including hepatitis, cirrhosis, liver cancer, and non-alcoholic fatty liver disease. The primary goal is to promote early detection, accurate staging, and effective management of liver-related diseases. The rising prevalence of liver diseases, increased awareness and preventive approaches, and improvements in healthcare infrastructure across various regions have necessitated the adoption of liver disease diagnostics solutions. Additionally, supportive government initiatives and funding for liver disease research and management accentuate the need for liver disease diagnostics. However, liver disease diagnostics faces challenges related to the high costs of advanced diagnostic tests, discrepancies in liver disease diagnostic standards, and limited accessibility in low-resource settings. Moreover, the lack of specific biomarkers for certain liver diseases and the risks associated with invasive diagnostic procedures can hinder growth. However, key players are exploring cutting-edge developments such as non-invasive imaging technologies and biomarker discovery to circumvent technical and safety complications. Furthermore, the increasing integration of AI and ML in diagnostics, which promises enhanced accuracy and predictive analytics, also opens up new avenues for growth. Personalized medicine and genomics are also gaining traction, offering the potential for tailored diagnostic and therapeutic approaches.

Regional Insights

The Americas region, particularly the U.S. and Canada, is characterized by the presence of a robust healthcare architecture and favorable reimbursement policies for various disease conditions, thereby fuelling the growth in liver disease diagnostics. Innovations in non-invasive imaging techniques and bio-marker identification are areas where significant investments and patent applications are seen. Initiatives such as the American Liver Foundation's efforts to improve liver health reflect the sector's proactive approach. The European Union displays diverse consumer behavior due to varying healthcare systems and economic capabilities across member countries. However, the adoption of the European Association for the Study of the Liver Clinical Practice Guidelines is a key factor in standardizing liver disease diagnostics. Increased R&D expenditure and multinational collaborations, such as those within the EU Horizon 2020 program, showcase the dynamic environment of innovation in the region. APAC region shows a burgeoning need for liver disease diagnostics due to the growing prevalence of liver-related disorders, growing awareness about liver health, and government initiatives to expand healthcare facilities to marginalized communities. The adoption of digital healthcare services and solutions is also gaining traction in the APAC region, which could create new avenues of growth for the industry.

Market Insights
  • Market Dynamics

    The market dynamics represent an ever-changing landscape of the Liver Disease Diagnostics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
    • Market Drivers
      • Increase in the Prevalence of Acute and Chronic Liver Diseases
      • Development of Government and Non-Government Awareness Programs
      • Consumer Inclination Towards Minimally Invasive Diagnostic Systems
      • Market Restraints
        • High Cost of Diagnostic Devices and Lack of Skilled Professionals
        • Market Opportunities
          • Technological Advancements in Diagnostic Systems
          • Improving Healthcare Access in Economies
          • Market Challenges
            • Complexity Associated with Liver Diagnostic Systems
            • Market Segmentation Analysis
              • Diagnosis Technique: Ongoing advances to improve imaging modalities for liver disease diagnosis
              • End-user: Expansion of hospitals across the world supported by government initiatives for developing robust healthcare infrastructure
              • Market Disruption Analysis
              • Porter’s Five Forces Analysis
              • Value Chain & Critical Path Analysis
              • Pricing Analysis
              • Technology Analysis
              • Patent Analysis
              • Trade Analysis
              • Regulatory Framework Analysis
              FPNV Positioning Matrix

              The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Liver Disease Diagnostics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

              Market Share Analysis

              The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Liver Disease Diagnostics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

              Recent Developments
              • E-Scopics Announces Commercial Launch Of Hepatoscope in the Us And Opens its Subsidiary in the US

                E-Scopics, a provider of software-centric point-of-care ultrasound solutions, announced the commercial debut of its liver diagnostics technology, Hepatoscope, in the American market. The Hepatoscope offers an advanced ultraportable ultrasound system that can be utilized directly at the patient's bedside. This innovative device seamlessly incorporates the established technique of transient elastography to accurately measure liver stiffness measurement (LSM), along with advanced ultrasound imaging and quantification capabilities typically found in premium ultrasound equipment.

                Stone Diagnostics to Provide Fibronostics Liver Disease Test

                Stone Diagnostics partnered with Fibronostics to broaden access to an innovative artificial intelligence-driven liver disease diagnostic tool known as Liverfast across the U.S. The Liverfast test leverages an AI algorithm and a panel of 10 blood-based biomarkers to accurately assess liver fibrosis, steatosis, and functional activity. This collaboration aims to enhance laboratory operations, catering to the growing demand for Liverfast and prioritizing the crucial needs of healthcare providers and their patients.

                Predictive Health Intelligence Launches Tool For Undiagnosed Liver Disease

                Predictive Health Intelligence has unveiled the hepatoSIGHT tool, which is aimed at identifying individuals with previously undetected liver ailments through the analysis of historical blood test data. This innovative solution has shown promising results in pilot studies within the Somerset NHS Foundation Trust, demonstrating its capability to detect patients at risk for advanced liver disease at an early stage.
              Strategy Analysis & Recommendation

              The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Liver Disease Diagnostics Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

              Key Company Profiles

              The report delves into recent significant developments in the Liver Disease Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., Argon Medical Devices, Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioMérieux SA, Boston Scientific Corporation, Cook Medical Incorporated, Epigenomics AG, F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, Hepatiq, Inc., Hologic, Inc., Horiba, Ltd., Koninklijke Philips N.V., Laboratory Corporation of America Holdings, Medtronic PLC, Merck & Co., Inc., Perspectum Ltd., Quest Diagnostics Incorporated, Randox Laboratories Ltd., Ri.Mos. Srl, Siemens Healthineers AG, and Thermo Fisher Scientific, Inc..

              Market Segmentation & Coverage

              This research report categorizes the Liver Disease Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:
              • Diagnosis Technique
                • Biopsy
                • Endoscopy
                • Imaging
                • Laboratory Tests
                • End-user
                  • Hospitals
                  • Laboratories
                  • Region
                    • Americas
                      • Argentina
                      • Brazil
                      • Canada
                      • Mexico
                      • United States
                        • California
                        • Florida
                        • Illinois
                        • New York
                        • Ohio
                        • Pennsylvania
                        • Texas
                        • Asia-Pacific
                          • Australia
                          • China
                          • India
                          • Indonesia
                          • Japan
                          • Malaysia
                          • Philippines
                          • Singapore
                          • South Korea
                          • Taiwan
                          • Thailand
                          • Vietnam
                          • Europe, Middle East & Africa
                            • Denmark
                            • Egypt
                            • Finland
                            • France
                            • Germany
                            • Israel
                            • Italy
                            • Netherlands
                            • Nigeria
                            • Norway
                            • Poland
                            • Qatar
                            • Russia
                            • Saudi Arabia
                            • South Africa
                            • Spain
                            • Sweden
                            • Switzerland
                            • Turkey
                            • United Arab Emirates
                            • United Kingdom


                            Please Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase in the Prevalence of Acute and Chronic Liver Diseases
5.1.1.2. Development of Government and Non-Government Awareness Programs
5.1.1.3. Consumer Inclination Towards Minimally Invasive Diagnostic Systems
5.1.2. Restraints
5.1.2.1. High Cost of Diagnostic Devices and Lack of Skilled Professionals
5.1.3. Opportunities
5.1.3.1. Technological Advancements in Diagnostic Systems
5.1.3.2. Improving Healthcare Access in Economies
5.1.4. Challenges
5.1.4.1. Complexity Associated with Liver Diagnostic Systems
5.2. Market Segmentation Analysis
5.2.1. Diagnosis Technique: Ongoing advances to improve imaging modalities for liver disease diagnosis
5.2.2. End-user: Expansion of hospitals across the world supported by government initiatives for developing robust healthcare infrastructure
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis
6. Liver Disease Diagnostics Market, by Diagnosis Technique
6.1. Introduction
6.2. Biopsy
6.3. Endoscopy
6.4. Imaging
6.5. Laboratory Tests
7. Liver Disease Diagnostics Market, by End-user
7.1. Introduction
7.2. Hospitals
7.3. Laboratories
8. Americas Liver Disease Diagnostics Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Liver Disease Diagnostics Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Liver Disease Diagnostics Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.3.1. E-Scopics Announces Commercial Launch Of Hepatoscope in the Us And Opens its Subsidiary in the US
11.3.2. Stone Diagnostics to Provide Fibronostics Liver Disease Test
11.3.3. Predictive Health Intelligence Launches Tool For Undiagnosed Liver Disease
12. Competitive Portfolio
12.1. Key Company Profiles
12.2. Key Product Portfolio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings